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Abstract
Cannabinoid receptor 1 (CB1 receptor) controls several neuronal functions, including
neurotransmitter release, synaptic plasticity, gene expression and neuronal viability.
Downregulation of CB1 expression in the basal ganglia of patients with Huntington’s disease (HD)
and animal models represents one of the earliest molecular events induced by mutant huntingtin
(mHtt). This early disruption of neuronal CB1 signaling is thought to contribute to HD symptoms
and neurodegeneration. Here we determined whether CB1 downregulation measured in patients
with HD and mouse models was ubiquitous or restricted to specific striatal neuronal
subpopulations. Using unbiased semi-quantitative immunohistochemistry, we confirmed previous
studies showing that CB1 expression is downregulated in medium spiny neurons of the indirect
pathway, and found that CB1 is also downregulated in neuropeptide Y (NPY)/neuronal nitric
oxide synthase (nNOS)-expressing interneurons while remaining unchanged in parvalbumin- and
calretinin-expressing interneurons. CB1 downregulation in striatal NPY/nNOS-expressing
interneurons occurs in R6/2 mice, HdhQ150/Q150 mice and the caudate nucleus of patients with
HD. In R6/2 mice, CB1 downregulation in NPY/nNOS-expressing interneurons correlates with
diffuse expression of mHtt in the soma. This downregulation also occludes the ability of
cannabinoid agonists to activate the pro-survival signaling molecule cAMP response element-
binding protein in NPY/nNOS-expressing interneurons. Loss of CB1 signaling in NPY/nNOS-
expressing interneurons could contribute to the impairment of basal ganglia functions linked to
HD.
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Introduction
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disease caused by a
poly-glutamine expansion of the protein huntingtin (Htt) resulting in the degeneration of
striatal γ-aminobu tyricacid (GABA)ergic neurons, glutamatergic cortical neurons and
hippocampal neurons (Group, 1993; Rosas et al., 2003). Electrophysiological recordings
from HD mouse models have demonstrated that striatal medium spiny neuron (MSN)
excitability changes from hyperexcitable to hypoexcitable; a shift in the balance of
glutamatergic and GABAergic signaling that augments as disease progresses (Cepeda et al.,
2003, 2004; Andre et al., 2006; Cummings et al., 2010). In addition, changes in the number
of GABAergic interneurons expressing neuropeptide Y (NPY) or calretinin have been
reported, and could contribute to the increased GABAergic tone in the striatum (Dawbarn et
al., 1985; Massouh et al., 2008). Accordingly, patients with HD exhibit severe debilitating
symptoms linked to the dysfunction of the basal ganglia (e.g. chorea and dystonia) that
typically develop after the onset of cognitive impairments (Walker, 2007). Together these
studies suggest that aberrant neuronal activity in the basal ganglia contributes to both the
symptomatology and the progression of neurodegeneration associated with HD.
Presynaptic cannabinoid receptor 1 (CB1 receptor) is expressed by both GABAergic and
glutamatergic terminals (Herkenham et al., 1991; Matyas et al., 2006). Activation of these
G-protein-coupled receptors inhibits presynaptic neurotransmitter release and regulates
synaptic plasticity in the striatum (Gerdeman & Lovinger, 2001; Marsicano et al., 2003;
Kofalvi et al., 2005; Kreitzer & Malenka, 2005). Thus, the downregulation of CB1 receptors
in HD mouse models could participate in the reported dysregulation of both GAB-Aergic
neurotransmitter release and synaptic plasticity measured in these models (Cepeda et al.,
2003, 2004; Cummings et al., 2010). Downregulation of total CB1 receptor expression in the
basal ganglia of adult patients with HD before symptom onset is well established, and has
recently been detected in pre-symptomatic patients with HD by positron emission
tomography (PET) imaging (Glass et al., 1993, 2000; Dowie et al., 2009; Van Laere et al.,
2010). CNR1 mRNA and CB1 receptor expression also decreases in the striatum of pre-
symptomatic R6/1 and R6/2 HD mouse models (Mangiarini et al., 1996; Denovan-Wright &
Robertson, 2000). Recent evidence indicates that decreases in CB1 receptor expression are
likely due to mutant (m)Htt disrupting CNR1 mRNA transcription, and that this deficit
results in a functional loss of CB1 receptor-mediated regulation of GABA release (Blazquez
et al., 2011; Chiodi et al., 2011). Here we sought to determine whether CB1 receptor loss is
ubiquitous or restricted to specific striatal neuronal subpopulations.
Materials and methods
Antibodies and drugs
The following antibodies were used in this study: CB1 (L15 pAb guinea pig 1 : 2000;
Berghuis et al., 2007); NPY [pAb rabbit 1 : 4000; Immunostar (Hudson, WI, USA) cat#
22940; mAb mouse 1 : 2000; Grouzmann et al., 1992]; leucine-enkephalin [pAb rabbit 1 :
500; Millipore (Billerica, MA, USA) cat# AB5024]; Substance P (pAb rabbit 1 : 4000;
Millipore cat# AB1566); parvalbumin (pAb rabbit 1 : 500; Immunostar cat# 24428);
phosphorylated cAMP response element-binding protein (pCREB) [(p-Ser133) pAb rabbit
1 : 800; Cell Signaling Technology (Danvers, MA, USA) cat# 9198]; mHtt (mAb mouse
clone mEM48 1 : 300; Millipore cat# MAB5374); calretinin (pAb rabbit 1 : 1000; Millipore
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cat# AB5054); neuronal nitric oxide synthase (nNOS; CH3-terminal, pAb 1 : 1000 rabbit;
Immunostar cat# 24287); goat anti-rabbit Alexa-488, 555 and 647 [1 : 500; Invitrogen
(Grand Island, NY, USA) cat# A11034, A21429, A21245]; goat anti-guinea pig Alexa-488
(1 : 500; Invitrogen cat# A11073); and goat anti-mouse Alexa-555 and 647 (1 : 500;
Invitrogen cat# A21422, A21236). WIN 55,212-2 was purchased from Tocris Biosciences
(Minneapolis, MN, USA).
R6/2 mice colony
Mice were housed in a specific pathogen-free facility in accordance with the National
Institutes of Health, and the Institutional Animal Care and Use Committee at the University
of Washington approved all experiments. Enrichment and ad libitum access to food and
water were provided, and a 12-h light : dark cycle was maintained in the facility. R6/2 and
wild-type littermates were given a wet food mash in addition to dry pellets beginning at 9
weeks old. Both female and male heterozygous and wild-type littermates were used in this
study. The colony was maintained by breeding 6–8-week-old R6/2 males with two CBA/
C57Bl/6 females (Jackson Labs, Bar Harbor, ME, USA). The average CAG repeat length
was 114.1 ± 0.3 (n = 10), and was determined by polymerase chain reaction (PCR) from tail
snips by Laragen (Culver City, CA, USA). CB1 receptor knockout colony was maintained
by breading homozygote males with homozygote females from 6 to 8 weeks old (Marsicano
et al, 2002). Experimenters were blind to the gender, genotype and age of all mice during
tissue processing, image collection and digital image analysis.
Quantitative PCR (qPCR)
The cortex and striatum of R6/2 and littermate wild-type mice (4, 6, 8 and 12 weeks old)
were dissected and rapidly stored in RNAlaterv® (Invitrogen). qPCR assays were performed
using LightCycler 480 system [Roche Applied Science (Branchburg, NJ, USA)]. Probes for
CB1 receptor were from Roche Applied Science (Universal Probe Library: Set #47) and
hypoxanthine phosphoribosyltransferase 1 (hprt1) from Applied Biosystems (Carlsbad, CA,
USA) (VIC-tgcaaatacgaggagtcctgttgatgttgc-TAMRA). Primer sequences were: CNR1
forward 5′-cgttcaaggagaacgaggac-3′ and reverse 5′-tgaagcactccatgtc-cataa-3′; HPRT1
forward 5′-cctaagatgagcgcaagttgaa-3′ and reverse 5′-ccacaggactagaacacctgctaa-3′.
Amplifications were run using a Stratagene Mx3000P QPCR system, and consisted of 30-
min incubation at 45 °C, followed by 10 min at 95 °C, and 40 cycles of 1 min at 95 °C and
30 s at 60 °C.
Human tissue sections
The University of Washington Institutional Review Board approved this study. Appropriate
measures for the protection of patient privacy were used. Paraffin-embedded human
caudate-putamen tissue samples from HD and healthy patients were supplied by the
University of Washington Alzheimer’s Disease Research Center [ADRC; grant # P50
AG05136 (Seattle, WA, USA)]. Five patients with HD and age-matched non-HD patients
were studied by semi-quantitative immunohistochemistry [sq-IHC; genotype, age, gender
and Vonsattel grade were (Vonsattel et al, 1985): non-HD 74 female, non-HD 77 female,
non-HD 78 male, non-HD 67 male, non-HD 52 male, HD 55 male (3), HD 20 female (3),
HD 55 male (3), HD 43 male (2–3), HD 74 male (3)]. The patients with HD died from
complications due to HD, while the non-HD patients died from non-CNS diseases and had
normal brains.
Immunohistochemistry
Mice were killed and perfused with paraformaldehyde [PFA; 4% in phosphate-buffered
saline (PBS)], post-fixed for 24 h, and their brains cryoprotected in 15% sucrose (24 h)
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followed by 30% sucrose (48 h). Coronal sections that included the corticostriatal, globus
pallidus or substantia nigra regions (30 µm) were prepared using a microtome, and then
stored in PBS at 4 °C until processing. Sections from R6/2 mice and wild-type littermates
were processed/ stained in parallel as follows – free-floating sections were rinsed 3× with
PBS and incubated for 90 min at room temperature (RT) in PBS supplemented with donkey
serum (5%) and Triton X-100 (1%). Primary antibody combinations were prepared as a
master stock in PBS supplemented with donkey serum (2.5%) and Triton X-100 (0.5%), and
applied to sections for 78 h at 4 °C with gentle agitation. Sections were then rinsed 8× with
PBS supplemented with Tween-20 (0.05%, at RT) and incubated with secondary antibodies
diluted in PBS supplemented with donkey serum (2.5%) and Triton X-100 (0.5%) for 1 h at
RT with gentle agitation, followed by seven rinses with PBS and one rinse with deionized
water. Sections were mounted onto slides and allowed to dry for ~ 18 h, after which cover
slips were mounted with Vectashield and sealed with nail polish. For CREB phosphorylation
studies, 12-week-old R6/2, CB1 receptor knockout and wild-type littermates were injected
with either vehicle (cremophore : ethanol : saline, 1 : 1 : 18) or WIN 55,212-2 (10 mg/kg,
i.p.), returned to their home cage for 30 min, and then killed, perfused with 4% PFA, their
brains dissected and stored in 10% neutral buffered formalin for paraffin embedding. Human
and pCREB paraffin-embedded slices (5 and 4 µm, respectively) were deparaffinized with
3×5 min xylene washes followed by rehydrating washes in ethanol and antigen retrieval in
citrate buffer (10 mM). Following addition of a hydrophobic barrier using an ImmunoPen™
(Millipore), sections were stained with the same protocol as the free-floating sections.
Microscopy
Dual-labeled images were collected on a Zeiss Axio Observer Z1 equipped with a Pan-
Apochromatic 10×/0.3 numerical aperture (NA) air objective (to count somatic population)
or a 63×/1.4 NA oil objective, ORCA-ER 1394 CCD camera [Hamamatsu (Hamamatsu
City, Japan)] and AxioVision software [version 4.7.1, Zeiss (Jena, Germany)]. Illumination
was set at 70% attenuation to limit photo bleaching and deconvolved using an Apotome
(Optical Sectioning Average: medium; Noise: 3). Triple-labeled images were acquired using
a Leica SP1 Confocal Laser Scanning microscope with a 40×/1.25 NA oil objective coupled
to an argon laser (excites Alexa488), a DPSS laser (excites Alexa555) and a helium/neon
laser (excites Alexa647) at the Keck Microscopy Facility of the University of Washington.
Four scans were averaged using a 4× digital zoom with a medium scan rate and pinhole set
at 102.9 µm. Sections that underwent parallel IHC staining were imaged using the same
exposure settings. Five images of the dorsolateral striatum and layer V/VI of the
sensorimotor cortex were taken per slice, and were processed for publication in parallel
using Photoshop.
Semi-quantitative image analysis and statistics
Dual- and triple-labeled images were analysed and quantified using ImageJ (National
Institutes of Health). Each channel was split into an individual image, and the mean intensity
and standard deviation of each fluorophore in each image was measured. Background signal
was removed by creating regions of interest (ROIs) for each fluorophore and setting the zero
threshold value to the mean + standard deviation (Table 1). This threshold was used to
analyse the 1/3 brightest pixels in the Poisson distribution of pixel intensity as the mean
intensity is composed of a large majority of background intensities, as revealed by parallel
staining of CB1R−/− tissue. While this threshold excludes ‘weakly’ stained synapses, the
remaining pixels that are analysed and quantified are comprised of positively stained pixels.
ROIs 1–2 were used to collect the average intensity of each fluorophore, and selectively
quantify axons and cell bodies that have positive staining. ROI 3 was created by making
binary masks of each ROI and using the ‘AND’ function to create new ROIs that only
contain regions with overlapping positive pixels from the original ROIs (Table 1). The
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‘Analysed Particles’ function was then used to extrapolate the mean and standard deviation
for each channel in each ROI. To quantify pCREB and mHtt levels, ROIs were hand-drawn
around positively labeled somas as determined by thresholding the interneuron marker to a
mean + standard deviation (interneuron soma ROI). Positive pCREB or mHtt in interneurons
was determined by thresholding total pCREB or mHtt staining to a mean + standard
deviation (pCREB/mHtt ROI) and combining it with the interneuron soma ROI using the
‘AND’ function in each image (pCREB/mHtt NPY ROI). The ‘Analysed Particles’ function
was then used to extrapolate the mean and standard deviation for each channel in each ROI.
Neurons whose percent area of pCREB staining to NPY soma staining was < 10% or > 50%
[(# of pCREB NPY ROI-positive pixels/# of NPY soma ROI-positive pixels) *100%] were
excluded, so only interneurons that contained pCREB translocated to the nucleus were
quantified [based on the average percent area of positive pCREB pixels in NPY interneurons
with visible nuclei treated with either vehicle (24.9 ± 18.1%) or WIN 55,212–2 (42.2 ±
1.8%); these values specifically reported as standard deviations]. Mask statistics were then
used to calculate the mean and standard deviation for each channel in each mask. All values
were imported into Excel [Microsoft® Office 2008 Version 12.2.7 (Redmond, WA, USA)],
and means were normalized to wild-type expression for comparison. All values are
expressed as mean ± standard error of the mean.
Statistical analysis
Statistical analysis and graphs were generated using GRAPHPAD PRISM (version 4; San Diego, CA,
USA). Comparisons of mean intensities between genotype at specific ages were analysed by
Student’s t-test. Comparisons between interneuron subtypes within R6/2 mice or pCREB
levels between genotypes were analysed by one-way ANOVA with a Tukey’s post hoc analysis,
while a two-way ANOVA was used to analyse qPRC data. Data were considered significant if P
< 0.05.
Results
CB1 receptor expression is decreased in R6/2 mouse striatum
It is known that CB1 receptor expression is decreased in the basal ganglia of various HD
mouse models (Fernandez-Ruiz, 2009). In agreement with several studies, we found that
CNR1 mRNA expression decreased in R6/2 mice as a function of disease progression
(Denovan-Wright & Robertson, 2000; Luthi-Carter et al, 2000; McCaw et al, 2004;
Blazquez et al, 2011; Chiodi et al, 2011). Specifically, using qPCR we found that CNR1
mRNA is decreased by 25.6 ± 5.6% in the striatum of R6/2 at 4 weeks old, and that this
downregulation reached its lowest level at 6 weeks old (57.7 ± 4.8% compared with wild-
type: df = 1, F = 72.495, P < 0.05; Fig. 1A). CNR1 mRNA in the cortex of R6/2 mice
decreased by 20.3 ± 1.6% at 4 weeks old, and by 43.6 ± 2.5% at 12 weeks old (R6/2
compared with wild-type: df = 1, F = 18.839, P < 0.05; Fig. 1A).
To determine if the expression of CB1 receptor protein was concomitantly decreased to
CNR1 mRNA, a sq-IHC analysis of corticostriatal slices from R6/2 mice was performed.
Control experiments confirmed that CB1 receptor protein expression displays a stereotypical
axonal pattering in the striatum of wild-type mice [(Uchigashima et al, 2007; Fig. 1B], and
that this immunostaining is absent in CB1−/− mice (Fig. 1C, insert). Remarkably, CB1
receptor protein staining in R6/2 striatum appeared more punctate (Fig. 1C). When
quantifying CB1 receptor expression by sq-IHC and defining ROIs for CB1 receptor-positive
axons (see Materials and methods for details; Fig. 2A and B), we found that CB1 receptor
loss in the striatum of R6/2 mice was delayed and less pronounced compared with the loss
of CNR1 mRNA, reaching a 16.2 ± 3.9% decrease in CB1 receptor protein at 12 weeks old
as compared with wild-type littermates (CB1 receptor expression normalized to age-matched
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wild-type littermates: 4 weeks, P = 0.77; 8 weeks, P = 0.52; 12 weeks, P < 0.001; Fig. 1D).
CB1 receptor protein staining in layers V/VI of the sensorimotor cortex remained unchanged
throughout the disease progression (CB1 receptor expression normalized to age-matched
wild-type littermates: 4 weeks, P = 0.28; 8 weeks, P = 0.11; 12 weeks, P = 0.60; Fig. 1E).
Approximately 95% of the striatal neurons are GABAergic MSNs, which project to the
substantia nigra reticulata in the direct pathway and the globus pallidus in the indirect
pathway. Because CNR1 mRNA in R6/2 striatum is significantly decreased and the majority
of CB1 receptors traffic to presynaptic axon terminals following translation (Matyas et al.,
2006), we measured whether CB1 receptor expression in the substantia nigra reticulata and
the globus pallidus of R6/2 mice was also decreased. We found that at 12 weeks old, CB1
receptor protein levels in R6/2 mice were decreased in the globus pallidus by 26.4 ± 10.9%
compared with wild-type, while remaining unchanged in the substantia nigra reticulata [CB1
receptor expression normalized to age-matched wild-type littermates (globus pallidus): 4
weeks, P < 0.01; 8 weeks, P < 0.001; 12 weeks, P < 0.05; (substantia nigra reticulate): 4
weeks, P = 0.22; 8 weeks, P = 0.55; 12 weeks, P = 0.48; Fig. 1F]. Interestingly, the
combined fold decrease in CB1 receptor protein measured in both the globus pallidus and
the striatum at 12 weeks (13.9 + 26.4% = 40.3%) is within the range of the decrease in
CNR1 mRNA measured in the striatum (46.3%) at this age. This result suggests that the loss
of CNR1 mRNA in the striatum is not a ubiquitous decrease in CNR1 mRNA among all
neuronal subpopulations, but is rather a selective decrease in specific neuronal
subpopulations. Together, these results suggest that CB1 receptor downregulation occurs in
MSNs belonging to the indirect pathway and in a yet unidentified neuronal subpopulation
within the striatum.
Downregulation of CB1 receptor protein in the striatum is selective to both NPY/nNOS+
interneurons and indirect pathway MSNs
Studies reporting the electrophysiological measurements in the striatum of R6/2 mice
demonstrate that overall GABAergic transmission is increased at disease end-stage (12
weeks old), and CB1 receptor-mediated inhibition of GABA release is lost in 12-week-old
R6/2 mice (Cepeda et al., 2004; Chiodi et al., 2011). Here we tested if CB1 receptor
expression is changed in all subpopulations of striatal GABAergic neurons known to express
CB1 receptors: MSNs, parvalbumin interneurons, calretinin interneurons and NPY
interneurons (Fusco et al., 2004; Narushima et al., 2006; Uchigashima et al, 2007).
Cholinergic interneurons in the striatum of wild-type mice lack CB1 receptors and thus were
not analysed (Hohmann & Herkenham, 2000). To quantify CB1 receptor expression in these
neuronal subpopulations, we performed sq-IHC of corticostriatal slices from R6/2 mice and
their wild-type littermates (double-labeled with antibodies directed against CB1 receptors
and specific neuronal markers). For MSN, we stained for the direct (substance P) and
indirect (leucine-enkephalin) pathways, thus labeling the collaterals that project within the
striatum. To identify interneurons, we co-labeled for parvalbumin, calretinin or NPY (Fig.
2A and B). In agreement with the decrease of the CB1 receptor found in the globus pallidus,
a 14.2 ± 6.2% decrease in indirect pathway MSN axon collaterals was observed (CB1
receptor in leucine-enkephalin normalized to wild-type littermate: P = 0.025; Fig. 2C). CB1
receptor was also decreased by 20.3 ± 3.5% at NPY interneurons, while remaining
unchanged at parvalbumin and calretinin interneurons, as well as in the axonal collaterals of
direct pathway MSN within the striatum of R6/2 mice [CB1 receptor in neuronal subtypes
normalized to wild-type littermate (NPY): P < 0.001; (substance P): P = 0.54;
(parvalbumin): P = 0.68; (calretinin): P = 0.87; Fig. 2C].
A recent study has demonstrated that NPY interneurons in the striatum consist of two
distinct populations of GABAergic interneurons (Ibanez-Sandoval et al, 2011).
Approximately 90% of NPY interneurons are low-threshold spiking (LTS) interneurons that
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express NOS and somatostatin (NPY/nNOS+); the remaining 10% of NPY interneurons lack
somatostatin and NOS (NPY/nNOS—) and display a distinct electrophysiological profile,
suggesting they perform a unique role in the striatal microcircuitry (Ibanez-Sandoval et al,
2011). To test whether CB1 receptor expression was decreased in these subclasses of NPY
interneurons in 12-week-old R6/2 mice, corticostriatal slices were triple-labeled for CB1
receptor, NPY and nNOS. sq-IHC analysis on NPY/nNOS— interneurons showed no
significant decrease in CB1 receptor expression (CB1 receptor normalized to wild-type
littermates: P = 0.21; Fig 2D). These results indicate that the decrease of CB1 receptors in
NPY interneurons is selective to the main NPY interneuron subtype, the LTS NPY/nNOS+
interneurons.
Downregulation of CB1 protein in NPY interneurons of HdhQ150/Q150 knock-in mice and
human patients with HD
Decreased striatal CNR1 mRNA also occurs in the full-length HD mouse model (Lin et al,
2001; Woodman et al, 2007). Here we sought to determine if the expression of CB1 receptor
protein was also decreased in NPY interneurons in two full-length HD models
(HdhQ150/Q150 and BACHD; Woodman et al., 2007; Gray et al., 2008). Coronal
corticostriatal sections of HdhQ150/Q150 mice (16–17 months old) and BACHD (9 months
old) were co-labeled for CB1 receptor and NPY. Similar to what we detected in R6/2 mice,
CB1 receptor expression in the striatum of HdhQ150/Q150 mice was decreased by 15.8 ±
6.5% in the striatum as a whole (CB1 receptor in HdhQ150/Q150 normalized to wild-type
littermates: P = 0.019; data not shown) and by 13.5 ± 6.5% at NPY interneurons (CB1
receptor in NPY interneurons of HdhQ150/Q150 -normalized wild-type littermates: P = 0.042;
Fig. 3A). In contrast, CB1 receptor expression remained unchanged both in the striatum as a
whole (CB1 receptor in BACHD normalized to wild-type littermates: P = 0.12; data not
shown) and at NPY interneurons in BACHD mice compared with their wild-type littermates
(CB1 receptor in NPY interneurons of BACHD-normalized wild-type littermates: P = 0.23;
Fig 3A). These results suggest that not all HD mice models reproduce the downregulation of
CB1 receptor known to occur in patients with HD.
A recent PET study demonstrated that downregulation of CB1 receptor in the striatum of
human presymptomatic patients with HD can be detected (Van Laere et al., 2010), extending
autoradiography studies that had detected a global loss of CB1 receptor in the caudate and
putamen of patients with HD as early as grade 0 (neuropathological grading scale criteria of
Vonsattel and colleagues; Vonsattel et al., 1985; Glass et al., 2000). This loss has been
attributed to the loss of CB1 receptor from MSN, first from indirect pathway MSNs in early
stages of the disease and then spreading to direct pathway MSNs in later stages (Richfield &
Herkenham, 1994; Glass et al., 2000). To determine if CB1 receptors at NPY interneurons
are also downregulated in human patients with HD, sq-IHC was performed on the caudate
and putamen tissue sections from patients with HD. We found a 15.2 ± 3.6% decrease of
CB1 receptors in NPY interneurons located in the caudate nucleus of patients with HD
compared with non-HD patients [CB1 receptor in NPY interneuron of patients with HD
normalized to non-HD patients (caudate): P < 0.001; (putamen): P = 0.8; Fig. 3B]. These
results suggest that the decrease of CB1 receptors at NPY neurons is a common phenomenon
occurring in both human patients with HD and HD mouse models.
NPY interneurons display diffuse mHtt load in R6/2 mice
mHtt forms aggregates within the nucleus and micro-aggregates within the cytoplasma of
neuropila that have been implicated in disrupting specific cellular mechanisms, including
gene transcription and axonal protein transport, both of which control CB1 receptor
expression and distribution within neurons (Li et al, 1999; Lee et al, 2004). To investigate if
mHtt formed nuclear aggregates in NPY interneurons, corticostriatal slices were double-
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labeled for mHtt and the three GABAergic interneuron subtypes. We found that large mHtt
aggregates were prominently located in parvalbumin interneurons in the striatum of 12-
week-old R6/2 (Fig. 4A). While it is thought that mHtt aggregates in a cell-autonomous
manner, calretinin interneurons express very low levels of mHtt and do not display the large
aggregates observed in parvalbumin interneurons (Fig. 4B). Some NPY interneurons
displayed large aggregates similar to parvalbumin interneurons, but the majority of mHtt
expression within NPY interneurons appeared as diffuse staining suggesting the presence of
micro-aggregates (Fig. 4C). Interestingly, small mHtt aggregates were observed in some
NPY neurites (Fig. 4C1). Semi-quantitative analysis confirmed that parvalbumin
interneurons contain 130% higher levels of mHtt compared with calretinin interneurons and
105% higher levels compared with NPY interneurons [mHtt in interneuron subtypes
normalized to mHtt in calretinin interneurons: F = 15.73, P < 0.001 (parvalbumin vs.
calretinin, and parvalbumin vs. NPY); Fig. 4D]. These results indicate that the presence of
micro-aggregate mHtt correlates with the decrease in CB1 receptor expression in NPY
interneurons.
A recent study suggested that monomeric or micro-aggregates represent the toxic form of
mHtt that could participate in neurodegeneration (Miller et al, 2011). To determine if the
number of NPY cells is reduced in R6/2 mice, NPY-positive somas were outlined and
counted in both R6/2 mice and human patients with HD. We found that the overall number
of NPY interneurons within the striatum of R6/2 mice was not lost (11.7 ± 5.8 NPY
interneurons/ 500 000 µm2 in wild-type vs. 10.1 ± 5.4 NPY interneurons/ 500 000 µm2 in
R6/2; P = 0.07; Fig. 5A). However, closer inspection of the two subtypes of NPY
interneurons revealed that the number of NPY/nNOS– interneurons is significantly reduced
in the dorsolateral striatum of 12-weeks-old R6/2 mice (1.6 ± 0.3 NPY interneurons/500 000
um2 in wild-type vs. 0.4 ±0.1 NPY interneurons/500 000 µm2 R6/2; P = 0.012; data not
shown). In human patients with HD, NPY interneurons were spared in the caudate (where
CB1 receptor levels are decreased at NPY interneurons; 1.7 ± 0.29 NPY interneurons/500
000 µm2 in patients with HD vs. 1.6 ± 0.20 NPY interneurons/500 000 µm2 in non-HD
patients), but were significantly higher in the putamen [where CB1 receptors are spared; 3.5
± 0.40 NPY interneurons/500 000 µm2 in patients with HD vs. 1.8 ± 0.25 NPY interneurons/
500 000 µm2 in non-HD patients; F = 9.357, P < 0.001 (non-HD putamen vs. HD putamen,
HD putamen vs. HD caudate, HD putamen vs. non-HD caudate); Fig. 5B]. These results
confirm previous studies that also found an increase in the number of NPY interneurons in
the caudate and putamen of patients with HD (Dawbarn et al., 1985).
Functional loss of CREB signaling downstream of CB 1 receptors activation in striatal NPY
interneurons in R6/2 mice
Activation of CREB through phosphorylation of serine 133 (pCREB) regulates cell survival
pathways, and defects in this signaling pathway are thought to contribute to the
neurodegeneration of MSN in the dorsolateral striatum (Mantamadiotis et al., 2002). Acute
activation of CB1 receptors increases pCREB levels in the brain and, accordingly, CB1
receptor downregulation could lead to a decrease in pCREB levels at specific neuronal
subtypes (Rubino et al., 2006; Isokawa, 2009). To test if decreased CB1 receptor expression
in R6/ 2 mice affected CREB signaling, we treated 12-week-old R6/2 mice and their wild-
type littermates with the CB1 receptor agonist WIN 55,212–2 and measured changes in
pCREB levels in NPY interneurons located within the dorsolateral striatum by sq-IHC.
While CB1 receptor activation in wild-type mice caused a significant 12.4 ± 2.5% increase
in the amount of pCREB in striatal NPY interneurons of wild-type mice [pCREB in NPY of
R6/2 normalized to pCREB in NPY of wild-type littermate: F = 5.677, P < 0.001 (wild-type
WIN 55,212−2 vs. wild-type vehicle and knockout vehicle), P < 0.05 (wild-type WIN
55,212-2 vs. R6/2 vehicle and R6/2 WIN 55,212–2); Fig. 6A, B and E], this treatment did
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not increase pCREB in NPY interneurons of R6/2 or CB1 knockout mice (F = 5.677, P >
0.05; Fig. 6C – E). These results suggest that CB1 receptor downregulation results in a
functional loss of cannabinoid-dependent pCREB signaling in striatal NPY interneurons of
R6/2 mice.
Discussion
By using sq-IHC as an unbiased approach, we confirmed that CB1 receptor expression is
decreased in the indirect pathway MSN early in the disease of R6/2 mice, and discovered
that it is also decreased in NPY/nNOS+ interneurons but later in the disease progression. We
validated this result in a slower progressing (full-length) mHtt knock-in model of HD
(HdhQ150/Q150), as well as in the caudate nucleus of patients with HD. In R6/2 mice,
decreased CB1 receptor expression in NPY/nNOS+ interneurons correlated with diffuse
mHtt expression and occluded the cannabinoid-stimulated activation of pCREB signaling in
these cells. Due to the postulated role played by NPY/nNOS+ interneurons in regulating
basal ganglia function, this selective loss of CB1 receptor signaling in this class of
interneuron could contribute to disrupting basal ganglia function in HD.
Glass et al. first reported the loss of CB1 receptor from the globus pallidus in pre-
symptomatic patients with HD (Glass et al., 2000), a result that propelled many laboratories
to study if and how this early molecular dysfunction occurs in various HD cellular and in
vivo models. Our study shows that in R6/2 mice, early in the disease, CB1 receptor
expression is decreased in the globus pallidus, while it is not affected in the striatum (where
these terminals originate). Accordingly, striatal CNR1 mRNA, the majority of which is
likely from MSNs, also decreases early in disease, providing a correlation between the early
loss in both CNR1 mRNA in the neuronal soma and the loss of CB1 protein in the
presynaptic terminals of these neurons. Our results suggest that the majority of CNR1
mRNA loss measured in the striatum belongs to MSNs of the indirect pathway. This result
agrees with MSNs comprising >95% of the neurons of the striatum, and suggests that loss of
CB1 protein in indirect pathway MSN could contribute to the enhanced susceptibility of
these projections to neuronal dysfunction during HD pathogenesis. Our results obtained in
R6/2 mice extend earlier studies performed on post mortem patients with HD demonstrating
that CB1 receptor binding is first decreased in the globus pallidus of presymptomatic
patients with HD followed by loss in the striatum and the substantia nigra reticulata as the
disease progresses (Glass et al., 1993, 2000).
Decreases in CB1 protein expression in specific neuronal subtypes could be due to multiple
mechanisms. Evidence indicates that mHtt directly interferes with the molecular machinery
controlling CNR1 gene transcription, decreasing CNR1 mRNA expression in various HD
models (McCaw et al., 2004; Blazquez et al., 2011). Because the decrease in CB1 receptor
expression is specific to certain neuronal subtypes, it is unlikely that reduction in CNR1
transcription represents the sole molecular mechanism responsible for decreasing CB1
receptor expression in cells. mHtt is also known to form micro-aggregates in axons of MSN
that inhibit anterograde axonal transport of molecules to axonal boutons (DiFiglia et al.,
1997; Gunawardena et al., 2003; Lee et al., 2004; Her & Goldstein, 2008). One hypothesis is
that mHtt-mediated disruption of anterograde axonal transport could participate in the cell-
specific decrease of CB1 receptor expression at axonal boutons, possibly resulting in the
punctate staining of CB1 receptor observed in the striatum of R6/2 mice. The correlation
between the diffuse mHtt staining in the nucleus associated with mHtt aggregates in the
neuropila of NPY interneurons and the cell-specific decrease of CB1 receptor at these
interneurons supports a role for micro-aggregates in both of these mechanisms. Accordingly,
there is a correlation between the presence of large aggregate loads in parvalbumin
interneurons and the stability of CB1 receptors expression in these neurons. These results
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agree with in vitro studies showing that larger mHtt aggregates might represent a protective
mechanism (Arrasate et al., 2004). Interestingly, the BACHD mouse model accumulates
very few mHtt aggregates and lacks nuclear localization of mHtt in the striatum, while still
displaying a large aggregate load in the cortex (Gray et al., 2008). Thus, the lack of CB1
receptor loss in the striatum of BACHD mice could reflect a lack of transcriptional and
anterograde transport dysregulation in the striatum of this mouse model. Here our results
suggest that in addition to transcriptional dysregulation of CNR1, the trafficking of CB1
protein down axons of MSNs projecting to the globus pallidus might be impaired by mHtt
aggregates.
Decreased expression and functionality of CB1 receptor at NPY/ nNOS+ interneurons could
have multiple functional implications on striatal output. NPY interneurons comprise about
1% of neurons within the striatum and can be divided into two distinct subtypes that display
unique electrophysiological properties. Interestingly, the loss of CB1 receptor is specific to
the prominent NPY/nNOS+ subtype, which are LTS GABAergic interneurons that establish
synaptic connections with the distal dendrites of both MSN and cholinergic interneurons
(Kreitzer, 2009; Tepper et al., 2010). Paired recordings of NPY/nNOS+ interneurons onto
MSNs from healthy tissue revealed that these synapses induce weak inhibitory postsynaptic
currents (IPSCs; Gittis et al., 2010). Accordingly, CB1 receptor downregulation at
GABAergic synapses of NPY/nNOS+ interneurons would enhance GABA release onto
MSN and intensify these IPSCs, a response measured in MSNs from both R6/2 and
HdhQ150/ Q150 mice (Cepeda et al., 2004; Cummings et al., 2010). In support of this idea, a
study by Dehorter et al. showed that under conditions where dopamine is depleted in the
striatum – a condition observed in both Parkinson’s disease and HD – LTS NPY
interneurons switch from eliciting a weak GABAergic signal to large oscillating IPSCs onto
MSNs (Johnson et al., 2006; Dehorter et al., 2009; Callahan & Abercrombie, 2011). Because
the production and release of endocannabinoids are controlled by dopamine receptor
activation (Giuffrida et al., 1999; Kreitzer & Malenka, 2005), reduction of both dopamine-
mediated endocannabinoid production and downregulation of CB1 receptor signaling in
these interneurons could impair the corticostriatal-MSN-NPY/nNOS+ interneuron
microcircuits, and ultimately the output function of these neuronal connections forming the
basal ganglia.
To determine if decreased CB1 receptor expression affected NPY/ nNOS+ interneuron
physiology, we used sq-IHC to measure CB1 receptor agonist-induced increases in pCREB
levels in these cells. We chose this readout because activation of CREB by phosphorylation
controls both synaptic plasticity and enhanced cell survival, and loss of CREB binding
protein activity downstream of pCREB has been implicated in HD (Silva et al., 1998;
Finkbeiner, 2000). CB1 receptor activation increases pCREB levels in both mouse brain
(neuronal network model) and cells in culture (cell-autonomous model; Rubino et al., 2006;
Isokawa, 2009; Hudson et al., 2010). To date we still do not understand the molecular and
cellular details of the pCREB response induced by cannabinoids. One possibility is that
activation of CB1 receptors expressed by neurons connecting with NPY/nNOS+
interneurons regulates the amount of pCREB in these cells by producing endocannabinoids.
Specifically, activation of synaptic glutamatergic N-methyl-D-aspartic acid (NMDA)
receptors increases CREB phosphorylation (Hardingham et al., 2002; Mantamadiotis et al.,
2002), while activation of extrasynaptic NMDA receptor subunit 2B (NR2B)-containing
NMDA receptors, due to excessive glutamate release, opposes pCREB increases. Activation
of NMDA receptors also increases endocannabinoid production from neurons (Stella &
Piomelli, 2001). CB1 receptor activation decreases the level of glutamate release from
presynaptic terminals, thus decreased CB1 receptor activation could lead to excessive
glutamate release leading to the activation of extrasynaptic NR2B–containing NMDA,
which have been implicated in HD progression (Hardingham et al., 2002; Heng et al., 2009;
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Okamoto et al., 2009; Milnerwood et al., 2010). With regard to the involvement of a cell-
autonomous mechanism, CB1 receptors expressed on the soma and dendrites of neurons are
thought to activate neuroprotective pathways, including pERK, a signaling pathway
upstream of pCREB, which is critical for cell survival in neurons undergoing excitotoxic
challenges (Bouaboula et al., 1995; Derkinderen et al., 2003; Marsicano et al., 2003).
Experiments in heterologous cell models show that CB1 receptor activation increases
pCREB levels, demonstrating that CB1 receptors can directly couple to this signaling
pathway (Graham et al., 2006; Hudson et al., 2010). Because NPY/nNOS+ interneurons
receive sparse glutamatergic innervations (Gittis et al., 2010), we propose that the CB1
receptor activation leads to increases in pCREB in NPY/nNOS+ interneurons through a cell-
autonomous mechanism. Together, these results suggest that CB1 receptor downregulation
leads to a functional loss of cannabinoid-mediated control of pCREB signaling in striatal
NPY/nNOS+ interneurons of R6/2 mice.
In conclusion, our study identified an additional neuronal subtype with decreased CB1
receptor expression within the striatum of HD mice models and patients. Because of the
known function of these G-protein-coupled receptors in controlling neuron responses and
participation in neuronal networks (Palop et al., 2006; Miller & Bezprozvanny, 2010), as
well as the function of NPY/nNOS+ interneurons in regulating the output function of the
basal ganglia, our study suggests that loss of CB1 receptor function in NPY interneurons
might be involved in the symptoms and pathogenesis associated with HD.
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Abbreviations
CB1 receptor cannabinoid receptor 1
CREB cAMP response element-binding protein
GABA γ-aminobutyric acid
HD Huntington’s disease
Htt huntingtin protein
IPSC inhibitory postsynaptic current
LTS low-threshold spiking
mHtt mutant huntingtin
MSN medium spiny neuron
NA numerical aperture
NMDA N-methyl-D-aspartic acid
nNOS neuronal nitric oxide synthase
NPY neuropeptide Y
NR2B NMDA receptor subunit 2B
PBS phosphate-buffered saline
PCR polymerase chain reaction
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pCREB phosphorylated CREB
PET positron emission tomography
PFA paraformaldehyde
qPCR quantitative polymerase chain reaction
ROI region of interest
RT room temperature
sq-IHC semi-quantitative immunohistochemistry
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Fig. 1.
Expression of total CB1 receptor in the sensorimotor cortex and basal ganglia of R6/2 mice.
(A) qPCR time course of CNR1 mRNA in the cortex and striatum of R6/2 mice normalized
to percentage of levels measured in wild-type littermates (n = 3–5 mice; Str R6/2 vs. WT
genotype: df = 1, F = 72.495, *P < 0.05; Ctx R6/2 vs. WT genotype: df = 1, F = 18.839, *P
< 0.05; Str and Ctx R6/2 vs. WT age: ns, two-way ANOVA). (B and C) Representative CB1
receptor labeling in the striatum of 12-week-old wild-type mice displaying characteristic
axonal labeling that is decreased in 12-week-old R6/2 littermates (insert: CB1 receptor
labeling in CB1−/− scale bar: 20 mm). (D) Time course of total CB1 receptor expression
quantified by sq-IHC in the striatum of R6/2 compared with wild-type littermates [n = 4
mice (4 weeks), 5 mice (8 weeks), 4–5 mice (12 weeks); ***P < 0.001]. (E) Time course of
total CB1 receptor in the sensorimotor cortex of 12-week-old R6/2 and wild-type littermates
[n = 4 mice (4 weeks), 5 mice (8 weeks), 4–5 mice (12 weeks)]. (F) Time course of CB1
receptor expression in the globus pallidus and substantia nigra pars reticulata of R6/2 mice
quantitated by sq-IHC (n = 3 mice per age and genotype, *P < 0.05, **P < 0.01, ***P <
0.001). All sq-IHC values are expressed as mean ± SEM normalized to age-matched wild-
type CB1 receptor expression, and analysed by two-tailed Student’s t-test to their wild-type
littermates.
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Fig. 2.
sq-IHC analysis of CB1 receptor at neuronal subtypes and synapses in the striatum of 12-
week-old R6/2 mice. (A and B) Representative dual-labeled images of CB1 receptor (Lin et
al., 2001) and neuropeptide Y (NPY; Blazquez et al., 2011) interneurons in the striatum and
the regions of interest (ROIs; see Materials and methods) created to identify positive CB1
receptor pixels (CB1 ROI), NPY pixels (NPY ROI), and overlapping CB1 receptor and NPY
pixels [(CB1 ‘AND’ NPY ROI); scale bar: 20 mm]. (C) CB1 receptor expression at indirect
pathway [leucine-enkephalin (LEnk)] and direct pathway [substance P (SubP)] axonal
collaterals, parvalbumin (Parv) and NPY interneurons in the striatum of wild-type and R6/2
mice (n = 4–5 mice, *P < 0.05, ***P < 0.001). (D) CB1 receptor expression at NPY/
neuronal nitric oxide synthase (nNOS—) interneurons in the striatum of wild-type and R6/2
mice (n = 5 mice). All values are expressed as mean ± SEM normalized to age-matched
wild-type CB1 receptor expression, and analysed by two-tailed Student’s t-test to their wild-
type littermates.
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Fig. 3.
CB1 receptor expression at neuropeptide Y (NPY) interneurons in full-length HD mouse
models and human patients with HD. (A) sq-IHC analysis of striatal sections from wild-type
and HdhQ150/Q150 or BACHD mice co-labeled for CB1 receptor, and neuropeptide Y (NPY)
to quantify the expression of CB1 receptor at NPY interneurons [n = 3 mice
(Hdh150Q150/Q150 group), 3–4 mice (BACHD group); *P < 0.05]. (B) CB1 receptor
expression in NPY interneurons of the caudate and putamen of post mortem patients with
HD compared with non-HD patients (control; n = 5 patients per condition, ***P < 0.001).
All values are expressed as mean ± SEM normalized to age-matched wild-type CB1 receptor
expression, and analysed by two-tailed Student’s t-test to their wild-type littermates.
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Fig. 4.
Mutant huntingtin (mHtt) expression levels in GABAergic interneurons in the striatum of
12-week-old R6/2 mice. R6/2 striatal tissue sections dual-labeled for mHtt (green, left
column; scale bar: 50 µm) and parvalbumin (Parv; A), calretinin (B) or neuropeptide Y
(NPY; C) interneurons (red, middle column). Small inserts on the right are magnified
images of mHtt expression in the soma of each interneuron subtype as identified by a thin
arrow in the parent image (scale bar: 5 µm). (C3) Magnified image of an NPY-labeled
neurite (C2) containing a mHtt aggregate (C1, scale bar: 10 µm). (D) sq-IHC analysis of the
expression level of mHtt within each subtype of striatal interneuron normalized to calretinin
levels expressing levels close to background levels (n = 5 R6/2 mice, ***P < 0.001
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compared with calretinin and NPY subtypes). All values are expressed as mean ± SEM
normalized to mHtt mean intensity in calretinin interneurons, and analysed by one-way ANOVA
with Tukey’s post hoc analysis.
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Fig. 5.
Population of neuropeptide Y (NPY) interneurons in the striatum of 12-week-old R6/2 mice
and the caudate-putamen of patients with HD. (A) Number of NPY-positive soma in the
dorsolateral striatum of 12-week-old R6/2 compared with wild-type littermates (n = 10 mice
per genotype). (B) NPY-positive neurons in the caudate and putamen of HD and non-HD
(control) patients (n = 5 per group; ***P < 0.001 for patients with HD compared with the
population of NPY interneurons in the caudate and putamen of control and caudate of
patients with HD). All values are expressed as mean ± SEM per area, and were analysed by
a two-tailed Student’s t-test in (A) a one-way ANOVA, with Tukey’s post hoc analysis in (B).
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Fig. 6.
Phosphorylated cAMP response element-binding protein (pCREB) in striatal neuropeptide Y
(NPY) interneurons following in vivo WIN 55,212-2 administration. (A–D) Striatal sections
from 12-week-old R6/2 and wild-type littermates dual-labeled for pCREB (green) and NPY
(Blazquez et al., 2011) 30 min following i.p. administration of WIN 55,212-2 or vehicle
(scale bar: 100 µm). Enlarged images of NPY interneurons depicting the presence or
absence of nuclear pCREB staining (left three panels of A–D; scale bar: 10 µm). (E) sq-IHC
of pCREB increases in striatal NPY interneurons of 12-week-old R6/2 and wild-type
littermates 30 min following treatment with WIN 55,212-2 or vehicle (n = 5 mice; ***P <
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0.001). All values are expressed as mean ± SEM normalized to age-matched wild-type
pCREB expression, and analysed by a one-way ANOVA with Tukey’s post hoc test.
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Table 1
ROIs created for sq-IHC
ROI Gating Measurements
1 Mean + Standard Deviation CB1R mean intensity
2 Mean + Standard Deviation Neuronal subtype mean intensity
3 ROI 1 “AND” ROI 2 CB1R expression at neuronal subtype
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